An interventional study of Barbed suture and Conventional smooth suture in Isthmocele, Cesarean Scar Defect and Pelvic Pain, sponsored by Hospital Clinic of Barcelona. Recruiting at 1 site in Spain. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Hospital Clinic of Barcelona · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Pelvic Pain with a site in Spain — 6 open to participants now, 6 under way, none of them phase 3. Pelvic Pain · Spain.
Among the 27 studies in Pelvic Pain with a site in Spain, this one is the 3rd largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2024, is one of 16 with no phase, and was the 20th registered.
377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.
Browse Pelvic Pain studies →6 of the 27 studies in Pelvic Pain with a site in Spain are open now. Recruiting first, the newest first:
University of Alcala · Sites in Spain
Ages 18–40 · Women only
Instituto Sexológico Murciano · Sites in Spain
Ages 18+ · Women only
Hospital Universitari de Bellvitge · Sites in Spain
Ages 18–45 · Women only
University of Alcala · Sites in Spain
Ages 18–45 · Women only
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3
First in 2008; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 420 is above the median of 60 across 278 interventional studies indexed under Pelvic Pain.
Median enrollment 69 across the 22 interventional studies, 133 across the 5 observational. Of the 17 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
Hospital Clinic of Barcelona is the lead sponsor of 327 studies on the registry; 54 are open to participants now.
Hospital Clinic of Barcelona has 2 studies filed under Pelvic Pain — fewer than ten, so there is no comparison to draw.
1 of the studies in Pelvic Pain with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06955221Hospital Universitari de BellvitgeEffect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Pelvic Pain with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Pregnant women, irrespective of their pregnancy risk, who undergo a cesarean section for any reason will be randomized to one of two suturing techniques: conventional suture or barbed suture for uterine repair after the cesarean section. Following surgery, these patients will be followed up for clinical outcomes, ultrasound evaluation of the uterine scar, and study of the hypoxic-inflammatory environment of the uterine cavity.
A randomized controlled trial will be conducted among pregnant women, irrespective of their pregnancy risk, undergoing cesarean sections at a tertiary care hospital. Participants will be randomly assigned to one of two groups: the intervention group, which will receive barbed suture for myometrial repair following the cesarean section, or the control group, which will receive conventional smooth suture. This study aims to compare a range of outcomes related to clinical, ultrasonographic, and molecular parameters of the uterine scar and the development of isthmocele.
Main hypothesis: The use of barbed suture for hysterorrhaphy during cesarean section, compared to conventional smooth sutures, results in reduced ischemia and necrosis of the myometrial tissue, facilitating better healing. This is associated with a lower incidence of isthmocele at six months postpartum, and a decrease in its ultrasound dimensions, evaluated by transvaginal ultrasound with hysterosonography.
Secondary hypothesis:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Uterine closure following cesarean section is carried out using an unlocked single-layer barbed suture with an endometrium-free technique.
Device: Barbed suture
Uterine repair following cesarean section is performed using a conventional smooth polyglactin suture with a continuous single-layer, endometrium-free technique, in accordance with the standard procedure at our center.
Device: Conventional smooth suture
Size 0 barbed absorbable monofilament suture with unidirectional spikes that includes a loop in one of its ends, not requiring knots.
Size 1 smooth multifilament absorbable polyglactin suture.
Rate of Isthmocele
Rate of isthmocele at nine to twelve months after cesarean section examined by transvaginal ultrasonography with hysterosonography.
Time frame: Nine to twelve months after cesarean section.
Ultrasonographic Measurements of Isthmocele
Ultrasonographic characteristics of isthmocele measured by niche length, niche depth, niche width, residual myometrial thickness (RMT) and niche size (niche depth/niche depth+RMTx100\[%\]).
Time frame: Nine to twelve months after cesarean section.
Intrauterine molecular markers of hypoxia and inflammation
Concentrations of the following biomarkers will be assessed by analyzing an endocavitary lavage of the uterus: SDF-1/CXCL12 (an indirect marker of tissue hypoxia), G-CSF, IL-1β, IL-6, IL-10 and TNF-α (inflammatory cytokines).
Time frame: Nine to twelve months after cesarean section.
Symptoms
Evaluation of symptoms related to CSD six months after cesarean section, measured as the presence of one or more of the following: prolonged postpartum bleeding, spotting, abnormal menstrual bleeding, dysmenorrhea, pelvic pain and/or dyspareunia.
Time frame: Nine to twelve months after cesarean section.
Risk factors
Collection of individual data in relation to the patient characteristics and the surgical procedure to evaluate potential risk factors. Individual data: Age at inclusion, ethnicity, educational level, parity, number of cesarean deliveries, history of uterine surgery or other abdominal surgeries, body mass index, smoking status, gestational or pregestational diabetes, hypertension, other medical conditions. Surgical data: Location of the hysterotomy, need for additional hemostatic sutures, need for hemostatic material at the surgical site, requirement for antifibrinolytic or uterotonic treatment to control bleeding, estimated blood loss during the surgery.
Time frame: Through study completion, an average of 2 years.
Ultrasonographic myometrial texture patterns
Time frame: Nine to twelve months after cesarean section.
Stiffness of the uterine scar
Stiffness differences of the uterine scar between the two groups will be compared by measuring the strain ratio (SR).
Time frame: Nine to twelve months after cesarean section.
Perinatal outcomes in following pregnancies
Perinatal outcomes in subsequent pregnancies will be measured as the presence of one of the following: miscarriage, ectopic pregnancy, uterine rupture, placental accretism, cesarean delivery among others.
Time frame: Through study completion, an average of 4 years.
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2027, 37 months after the start.
Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 37 months is above that.
Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.
Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2027 → Dec 2027, on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Clinic of Barcelona →